For the Culture By The Culture. ISSN: 3064-9331.
Jersey reinvented itself. A forty-five square mile island once known for offshore finance is now exporting pharmaceutical-grade cannabis into Germany’s booming medical market. With strict regulation, heavy investment, and a government eager for diversification, Jersey has become an unlikely European powerhouse. The contradiction between local policing and global commerce tells the real story.
Thailand blew open its cannabis market, then tried to force it back under control. This feature tracks the country’s shift from prohibition to medical legalization, decriminalization, and regulatory backlash, exposing how weak enforcement, political pressure, and rushed policy turned a reform headline into a live case study in state correction.
Cannabis prohibition in the United States no longer survives on raids and panic films. It survives through ballot thresholds, legislative rewrites, regulatory choke points, and lobbying disclosures. This documented audit follows the filings behind legalization war chests, opposition strategies, and the institutional structures that still shape cannabis policy even after voters move on.
This new investigative series begins by confronting one of cannabis policy’s most durable myths. THC percentage became a convenient shortcut for harsher laws, even though higher potency has never equaled greater danger. Vol. 1 documents how numbers replaced evidence and how courts, media, and policy still punish people for a claim that cannot survive scrutiny.
As cannabis reform accelerates worldwide, the UN’s International Narcotics Control Board continues warning that decades old drug treaties still apply. This feature examines the INCB’s actual authority, the limits of treaty enforcement, and why global legalization is advancing despite institutional resistance rooted in prohibition era frameworks.
Reefer Report Card Vol. 30 tracks a week where legalization stalled while rollback efforts gained ground. Ballot initiatives threatened regulated markets, federal reform stayed stalled, and patients were left navigating uncertainty. Demand remained strong, but oversight weakened. Another week where cannabis survived while governance quietly failed.
